CROSSJECT |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.97 EUR | -2.48% |
|
-6.64% | -60.36% |
| May. 03 | Crossject: praised for extended agreement on Zepizure | CF |
| May. 02 | Crossject Signs A Geographic Extension of ZEPIZURE Commercialization Agreement in Europe | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2023 | 12.83M 13.92M | Sales 2024 * | 3.7M 4.02M | Capitalization | 74.91M 81.32M |
|---|---|---|---|---|---|
| Net income 2023 | -8M -8.68M | Net income 2024 * | -15M -16.28M | EV / Sales 2023 | 14.7 x |
| Net Debt 2023 * | 25.8M 28.01M | Net Debt 2024 * | 27.8M 30.18M | EV / Sales 2024 * | 27.8 x |
| P/E ratio 2023 * |
-3.46
x | P/E ratio 2024 * |
-4.93
x | Employees | 110 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 61.31% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | -2.48% | ||
| 1 week | -6.64% | ||
| Current month | -3.90% | ||
| 1 month | +5.35% | ||
| 3 months | -51.12% | ||
| 6 months | -54.13% | ||
| Current year | -60.36% |
1 week
1.95
2.13
1 month
1.902.29
Current year
1.835.96
1 year
1.835.96
3 years
1.415.96
5 years
1.045.96
10 years
1.0211.25
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 61 | 01-08-07 | |
Olivier Giré
PRN | Corporate Officer/Principal | - | 15-12-31 |
| Corporate Officer/Principal | - | 12-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Daniel Teper
BRD | Director/Board Member | 64 | 23-06-06 |
Eric Nemeth
BRD | Director/Board Member | 65 | - |
Philippe Monnot
CHM | Chairman | 65 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-16 | 1.97 | -2.48% | 63,580 |
| 24-05-15 | 2.02 | +0.50% | 27,485 |
| 24-05-14 | 2.01 | -0.25% | 55,139 |
| 24-05-13 | 2.015 | -4.95% | 48,197 |
| 24-05-10 | 2.12 | +0.47% | 53,219 |
Real-time Euronext Paris, May 16, 2024 at 11:24 am EDT
More quotes
Crossject specializes in manufacturing and marketing needleless drug self-injection. The group provides Zeneo, a prefilled and single-use device that can be used for intradermal, subcutaneous and intramuscular injections.
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.97
EUR
Average target price
5
EUR
Spread / Average Target
+153.81%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -60.36% | 81.42M | |
| +0.82% | 217M |
- Stock Market
- Equities
- ALCJ Stock
